BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//OTRADI - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.otradi.org
X-WR-CALDESC:Events for OTRADI
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260318T120000
DTEND;TZID=America/Los_Angeles:20260318T130000
DTSTAMP:20260217T230541Z
CREATED:20251028T220025Z
LAST-MODIFIED:20260217T230541Z
UID:10002377-1773835200-1773838800@www.otradi.org
SUMMARY:Virtual Lunch & Learn: AI-Powered Clinical Trials: De-Risking Enrollment\, Timelines\, and Investor Confidence for Biotech Leaders
DESCRIPTION:Clinical trials are the single biggest operational and financial risk for small to mid-size biotech companies. Fifty to eighty percent of trials miss enrollment targets\, unplanned amendments cost $150-300K each\, and database lock delays push readouts back months. For companies with just 18-24 months of runway\, every setback erodes investor confidence\, delays financing\, and gives faster rivals the edge. This session tackles the five pain points keeping CEOs awake: on-time First Patient In\, fewer costly amendments\, better enrollment and retention\, faster database lock\, and predictable execution that protects investor confidence. \nLearn how AI\, already delivering measurable results for IQVIA\, ICON\, and Syneos Health\, can cut timelines 20%\, boost recruitment 26%\, and preserve $15-22M of runway per Phase 2b/3 trial. Walk away with a practical roadmap from targeted pilots to portfolio-wide adoption that turns clinical trial risk into a competitive advantage. Join us and give your next trial the advantage it deserves. \nRegister for free HERE
URL:https://www.otradi.org/event/virtual-lunch-learn-3/
CATEGORIES:Lunch & Learn,OBI Programs/Events
END:VEVENT
END:VCALENDAR